ROSEN, A TOP-RANKED LAW FIRM, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – EW

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Edwards Lifesciences Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [2][3]. Group 1: Class Action Details - The Class Period for the lawsuit is from February 6, 2024, to July 24, 2024, inclusive [2]. - Investors who purchased Edwards securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 13, 2024 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Specifics - The lawsuit alleges that during the Class Period, defendants provided misleading information regarding Edwards' expected revenue for fiscal year 2024, particularly concerning the growth of its TAVR product [5]. - Defendants made claims about strong commitment to the TAVR platform and significant demand in lower-penetrated markets, which, when proven false, led to investor damages [5].